A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients

被引:38
作者
Picard, Nicolas
Premaud, Aurelie
Rousseau, Annick
Le Meur, Yannick
Marquet, Pierre [1 ]
机构
[1] Univ Hosp, Dept Pharmacol Toxicol, F-87042 Limoges, France
[2] Univ Hosp, Dept Nephrol, F-87042 Limoges, France
[3] Univ Limoges, Fac Med, Pharmacol Lab, Limoges, France
关键词
mycophenolate mofetil; sirolimus; kidney transplantation; metabolism;
D O I
10.1111/j.1365-2125.2006.02509.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To compare the pharmacokinetics of mycophenolic acid when given with either ciclosporin or sirolimus, and investigate in vitro the potential effect of ciclosporin, sirolimus, tacrolimus and everolimus on mycophenolic acid metabolism. Methods In renal transplant patients given mycophenolate mofetil in combination with ciclosporin (n = 19) or sirolimus (n = 12), concentration-time profiles of mycophenolic acid, mycophenolic-acid-phenyl-glucuronide, mycophenolic-acid-acyl-glucuronide and mycophenolic-acid-phenyl-glucoside were determined at one month post-transplant. The effect of immunosuppressive drugs on mycophenolic acid glucuronidation and glycosylation was investigated in vitro using human liver microsomes. Results The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L-1 (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L-1 (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05). In addition, the metabolite/mycophenolic acid AUC(0-9 h) ratios were significantly higher in patients cotreated with ciclosporin than with sirolimus, giving values of 1.8-fold (95% CI: 1.3-2.3; P = 0.0009), 2.6-fold (95% CI: 2.0-3.3; P < 0.0001) and 4.3-fold (95% CI: 2.6-6.0; P = 0.0016) for mycophenolic-acid-phenyl-glucuronide, mycophenolic-acid-acyl-glucuronide and mycophenolic-acid-phenyl-glucoside, respectively. In vitro, none of the immunosuppressive drugs tested inhibited mycophenolic acid metabolism. Conclusion Patients taking mycophenolate mofetil and sirolimus experience a higher exposure to mycophenolic acid and a lower exposure to mycophenolic acid metabolites than those being treated with mycophenolate mofetil and ciclosporin. This interaction is probably not caused by inhibition of mycophenolic acid glucuronidation or glycosylation, but is more likely to be due to the influence of ciclosporin on the excretion of mycophenolic acid metabolites into bile.
引用
收藏
页码:477 / 484
页数:8
相关论文
共 28 条
[1]   Can xipamide or tacrolimus inhibit the glucuronidation of mycophenolic acid in rat liver slices? [J].
Balogh, A ;
Merkel, U ;
Müller, D .
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2003, 54 (5-6) :375-379
[2]   The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, RS ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :815-832
[3]   The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes [J].
Bowalgaha, K ;
Miners, JO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) :605-609
[4]   Clinical pharmacokinetics of mycophenolate mofetil [J].
Bullingham, RES ;
Nicholls, AJ ;
Kanmm, BR .
CLINICAL PHARMACOKINETICS, 1998, 34 (06) :429-455
[5]   Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporin [J].
Flechner, SM ;
Goldfarb, D ;
Modlin, C ;
Feng, JY ;
Krishnamurthi, V ;
Mastroianni, B ;
Savas, K ;
Cook, DJ ;
Novick, AC .
TRANSPLANTATION, 2002, 74 (08) :1070-1076
[6]   Sirolimus (rapamycin)-based therapy in human renal transplantation -: Similar efficacy and different toxicity compared with cyclosporine [J].
Groth, CG ;
Bäckman, L ;
Morales, JM ;
Calne, R ;
Kreis, H ;
Lang, P ;
Touraine, JL ;
Claesson, K ;
Campistol, JM ;
Durand, D ;
Wramner, L ;
Brattström, C ;
Charpentier, B .
TRANSPLANTATION, 1999, 67 (07) :1036-1042
[7]   Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients [J].
Hübner, GI ;
Eismann, R ;
Sziegoleit, W .
THERAPEUTIC DRUG MONITORING, 1999, 21 (05) :536-539
[8]   A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital [J].
Innocenti, F ;
Undevia, SD ;
Ramírez, J ;
Mani, S ;
Schilsky, RL ;
Vogelzang, NJ ;
Prado, M ;
Ratain, MJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (05) :490-502
[9]   Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation [J].
Kiberd, BA ;
Lawen, J ;
Fraser, AD ;
Keough-Ryan, T ;
Belitsky, P .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (07) :1079-1083
[10]   Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats [J].
Kobayashi, M ;
Saitoh, H ;
Kobayashi, M ;
Tadano, K ;
Takahashi, Y ;
Hirano, T .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (03) :1029-1035